Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarafenacin for Overactive Bladder (Phase II, 0.2 mg vs 0.4 mg vs Placebo)
KCT0000207Phase 2Recruiting
- Sponsor
- Kwang Dong Pharmaceutical Co., Ltd.
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tarafenacin in overactive bladder (OAB), sponsored by Kwang Dong Pharmaceutical Co., Ltd.. Started Sep 2011; status: recruiting.
02
Drugs
tarafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on KCT0000207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000207.